Bicycle
Bicycle Therapeutics Lays Off 25% of Workforce After Genentech Collaboration Ends
Bicycle Therapeutics; layoffs; Genentech; R&D partnership; biotech; cost reduction; workforce reduction; strategic realignment
Bicycle Therapeutics Faces Stock Decline After Releasing Topline Data and Post-Hoc Analyses
Bicycle Therapeutics, stock decline, topline data, post-hoc analyses, cancer trials, zelenectide pevedotin, BT5528, metastatic urothelial cancer, Nectin-4 gene amplification.
Bicycle Therapeutics Gears Up for Future Milestones with $555 Million Capital Infusion
Bicycle Therapeutics, funding, catalysts, biotechnology, drug development, clinical trials, investors, capital infusion, milestones.